In a series of setbacks on the Uganda Stock Exchange, Ugandan pharmaceutical tycoon Emmanuel Katongole has experienced significant losses as the market value of his shares in Cipla Quality Chemical Industries Limited (CiplaQCIL) has fallen below $2 million.
CiplaQCIL, located in the suburb of Luzira in Uganda’s capital city, specializes in the production of triple-combination antiretroviral drugs, including Lumartem, an antimalarial drug, as well as generic Hepatitis-B medications such as Texavir and Zentair.
Recommended articles
- Teachers, students escape death as Sen. Obasanjo-donated classrooms collapse
- Traditional religion: Joblessness, idleness and feigned piety
- It’s not by writing speeches, Daniel Regha knocks Peter Obi again
- We didn’t withdraw VIP aides, police refute viral report
- Electoral malpractices: PDP appeals to DIG Egbetokun as Dapo Abiodun allegedly threatens Ogun police
- UBA targets superior customer experience delivery, launches CX School of Excellence for staff
- Monsurat Awodein impersonates govt agent, enmeshed Certificates of Sponsorship issuance fraud
- FirstBank jeopadising my son’s health over N200k, father cries out (Video)
The event would taking place for the Remo Fede
As the executive director of CiplaQCIL and a prominent figure in East Africa’s healthcare industry, Katongole holds a significant 2.79-percent stake in the company, which amounts to 101,933,042 ordinary shares.
Over the past few years, CiplaQCIL shares on the Uganda Stock Exchange have experienced a dramatic decline, dropping from Ush250 ($0.0681) to Ush70 ($0.019) as of Mon., July 17.
This downward spiral has resulted in substantial losses for the company’s shareholders, including Katongole, who owns a significant stake in the pharmaceutical manufacturing firm.
As a result of the continuous downward trend in the company’s shares, CiplaQCIL’s market capitalization has fallen below $70 million, leading to a significant devaluation of Emmanuel Katongole’s stake in the pharmaceutical firm to Ush7.14 billion ($1.95 million).
In an effort to pare losses and unlock value for its shareholders, CiplaQCIL has recently entered into a share sale agreement with Africa Capitalworks, a Mauritius-based firm. Under this agreement, Africa Capitalworks is set to acquire a 51.18-percent stake in CiplaQCIL.
This strategic investment by Africa Capitalworks aims to tap into growth opportunities, particularly in the realms of technology, innovation, and drug manufacturing.
The Mauritius-based investment firm is seeking approval from the Capital Markets Authority for the proposed deal, which, if approved, will substantially change the company’s shareholding structure.
Freelanews is the editorial byline of Freelanews.com, used for staff reports, news updates, press releases, and collaborative stories produced by the Freelanews Editorial Team.
